DOCSLIB.ORG

Desmoplastic Small Round Cell Tumor of the Kidney: a Case Report Dilek Ertoy Baydar1*† , Ayse Armutlu1†, Oguz Aydin2, Ayhan Dagdemir3 and Yarkin Kamil Yakupoglu4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Desmoplastic Small Round Cell Tumor of the Kidney: a Case Report Dilek Ertoy Baydar1*† , Ayse Armutlu1†, Oguz Aydin2, Ayhan Dagdemir3 and Yarkin Kamil Yakupoglu4 Ertoy Baydar et al. Diagnostic Pathology (2020) 15:95 https://doi.org/10.1186/s13000-020-01015-w CASE REPORT Open Access Desmoplastic small round cell tumor of the kidney: a case report Dilek Ertoy Baydar1*† , Ayse Armutlu1†, Oguz Aydin2, Ayhan Dagdemir3 and Yarkin Kamil Yakupoglu4 Abstract Background: Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive neoplasm seen in children and young adults, usually manifested by involvement of abdominal serosa. Here, we present an unusual case of primary DSRCT of kidney. Case presentation: The patient was an 8-year-old girl with a large renal mass which was confused with primitive neuroectodermal tumor (PNET) in the needle biopsy. The tumor had a variegated histology revealing frequent pseudo-rosette formations, pseudopapillary architecture, rhabdoid, clear or pleomorphic cells in addition to typical small round cell morphology and desmoplasia. It showed immunohistochemical features of DSRCT, and EWSR1 re- arrangement. Conclusions: Proffering this diagnosis is particularly difficult for tumors of viscera because of the incognizance of the entity in these locations. Moreover, DSRCT is a great mimicker and may get easily confused with more common kidney malignancies of childhood such as Wilms tumor, PNET/EWS, rhabdoid tumor, clear cell sarcoma, and other small round cell tumors as well as renal cell carcinomas. The distinction is critical as the accurate therapeutic approach will require correct diagnosis. Keywords: Desmoplastic small round cell tumor, Kidney, WT1, EWSR1, Case report Background are extremely rare with only a few cases reported in Desmoplastic small round cell tumor (DSRCT) is a rare, lungs, ovary, soft tissues, bones, intracranial and sinona- distinct entity that was first described by Gerald and sal locations [2, 3]. Rosai in 1989 [1]. Predilection for adolescent males, DSRCT primary of the kidney was first described by predominant intraabdominal location involving serosal Su, et al. [4] in 2004 and since then only a total of surfaces, nesting pattern of growth, focal rhabdoid 12 cases have been reported in the literature (Table 1) morphology, prominent desmoplastic reaction, immuno- [5–12]. Herein, we present the thirteenth case of histochemical reactivity for epithelial, neural and muscle renal DSRCT that had variant histological features markers, and highly aggressive clinical behavior are its mimicking various types of other neoplasia. The main features. DSRCT shows a specific reciprocal pathologic diagnosis of this entity can be markedly chromosomal translocation, t(11;22)(p13;q12) (EWSR1- challenging when it develops in visceral organs such WT1 fusion) which generates a chimerical protein with as kidney and especially if diverse and confounding transcriptional regulatory activity. Extraserosal DSRCTs microscopic features are present. * Correspondence: [email protected]; [email protected] Case presentation † Dilek Ertoy Baydar and Ayse Armutlu contributed equally to this work. Clinical history 1Department of Pathology, Koc University School of Medicine, Topkapi, 34010 Istanbul, Turkey An 8-year-old girl complained of abdominal pain and an Full list of author information is available at the end of the article ultrasonography found a large mass in her left kidney. © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Table 1 Clinicopathologic features of the cases described in the literature (a) Ertoy Baydar Age Clinical R/L Gross Findings Microscopic Findings Immunohistochemistry Molecular Therapy Follow-up Publication / presentation side pathology Sex Case 41 / Incidental Left Renal mass at hilar region, Nests of small round blue cells CK (AE1/AE3) (+), Desmin (+), RT-PCR Surgery Alive (NED) at Su, et al., et al. Diagnostic Pathology 1 F 6x5x5 cm, invaded into within desmoplastic stroma; Vimentin (+), NSE (+), EMA (−), showing 18th mo. [4] perirenal soft tissue occasional rosette-like forma- CK7 and 20 (−), CD99 (−), S100 EWSR1-WT1 tions; necrosis and numerous (−), Chromogranin (−), fusion mitotic figures Synaptophysin (−) Case 7 / F Gross Left Confined within renal Small round undifferentiated Desmin (+), WT-1 (+), CD99 (+), RT-PCR Surgery + CT Alive (NED) at Eaton, 2 hematuria capsule, 3.7 × 3.7 × 3.2 cm cells, necrosis and epithelioid SMA (+), EMA (+), Myogenin (−) showing 12th mo. et al., [5] following a fall component EWSR1-WT1 fusion (2020)15:95 Case 6 / F Renal mass Left 3.7 cm mass confined to Nests, sheets or cords of small CK (+), Desmin (+), Vimentin (+), Dual color FISH Neoadjuvant Alive (NED) Egloff, 3b (no details kidney undifferentiated cells; WT1 (+), FLI-1 (+), CD56 (+); EMA showing CT + Surgery 24th mo. et al., [6] about clinical numerous mitotic figures, no (−), CD99 (−), Myogenin (−), S100 EWSR1-WT1 and Wang, presentations) desmoplasia (−), Chromogranin (−), Synapto- translocation et al., [7] physin (−) and RT-PCR showing Case 6 / F Left 13.4 cm mass showing CK (+), EMA (+), Desmin (+), EWSR1-WT1 Surgery + CT Pulmonary Wang, 4 renal sinus invasion Vimentin (+), CD99 (+), WT1 (+), fusion metastasis at et al., [7] FLI-1 (+), CD56 (+), Myogenin (−), 32nd mo. CT, S100 (−), Chromogranin (−), stem cell Synaptophysin (−) transplantation. NED a year later Case 6 / F Left 9 cm mass with perirenal CK (+), EMA (+), Desmin (+), Alive (NED) at 5 soft tissue and renal sinus Vimentin (+), CD99 (+), WT1 (+), 22nd mo invasion FLI-1 (+), CD56 (+), Myogenin (−), S100 (−), Chromogranin (−), Synaptophysin (−) Case 8/ Left 9.2 cm mass with renal EMA (+), Desmin (+), Vimentin (+), Intraabdomimal 6 M sinus invasion CD99 (+), WT1 (+), FLI-1 (+), CD56 recurrence and (+), CK (−), Myogenin (−), S100 liver metastasis (−), Chromogranin (−), Synapto- at 20th mo. physin (−) CT. AWD Case 14 / Gross Left 17.5x12x11 cm mass Small ovoid-spindle blue cells EMA (+), Desmin (+), Vimentin (+), RT-PCR Surgery + Liver and lung Collardeau- 7 F hematuria, invading renal sinus and in solid sheets and large nests; WT1 (+), CD56 (+), Chromogranin showing CT + local RT metastases at Frachon, fever and self- perinephric fat, and focally rare rosette-like structures; nu- (focal +), Synaptophysin (rare +), EWSR1-WT1 8th mo. et al., [8] disvovered ab- extending to Gerota’s merous mitotic figures; tumor CK (AE1/AE3) (−), CD99 (−), S100 fusion dominal mass fascia; metastatic lymph thrombi in perinephric blood (−) node in hilar region vessels Case 10 / Gross Right 14 × 11 cm mass Small blue round cells with CK (+), Desmin (+), CD99 (−), WT1 RT-PCR Surgery + Liver, lung, da Silva, 8 M hematuria, desmoplasia; occasional (+), FLI-1 (+); S100 (−), Chromo- showing CT + local RT bone, lymph et al., [9] abdominal rosette-like formations. granin (−), Synaptophysin (−) EWSR1-WT1 node pain, palpable fusion metastases. Page 2 of 9 mass AWD at 12th mo Table 1 Clinicopathologic features of the cases described in the literature (a) (Continued) Ertoy Baydar Age Clinical R/L Gross Findings Microscopic Findings Immunohistochemistry Molecular Therapy Follow-up Publication / presentation side pathology Sex Case 20 / Renal mass and Right 8 cm mass with areas of Elongated to round cells with CK (+), Desmin (+), Vimentin (+), FISH showing Surgery Pulmonary Rao, et al., et al. Diagnostic Pathology 9 M pulmonary hemorrhage and necrosis, scant cytoplasm in sheets and CD56 (+); WT1 (cytoplasmic +), EWSR11 metastases at [10] nodules invading renal vein grossly occasionally a vague nodular CD99 (−), MyoD1 (−), NSE (−), rearrangement presentation, (no details pattern, frequent mitotic RCC Ag (−), EMA (−), Myogenin and RT-PCR local recurrence about clinical activity, lacked prominent (−), S100 (−) showing after surgery. presentations) desmoplasia EWSR1-WT1 Exitus at 2nd fusion year Case 7/ Gross Left Polypoid mass confined to Spindled and polygonal tumor CD99 (+), Vimentin (+), Desmin FISH showing Surgery + Alive (NED) Eklund 10 M hematuria, the renal collecting system, cells, rare rosettes, low mitotic (focal+), Actin (focal+), WT1 EWSR1 CT + RT (duration et al., [11] microscopic extending into proximal rate (focal+), PAX2 (+); PAX8 (−) rearrangement, unknown) (2020)15:95 hematuria and and mid ureter, no karyotyping intermittent involvement of renal showing t(11; back pain 3 parenchyma 22) (p13;q12). years priorly Case 6/ Facial swelling Right 5.7 × 5.5 × 4.7 cm mass Sheets of poorly differentiated Bcl-2 (+), CD99 (+), desmin (+), RT-PCR No Metastatic Walton, 11 M and pain, with large areas of central round cells, no desmoplastic vimentin (+), CD56 (+), and FLI-1 showing information disease
Load more

Recommended publications
  • The Health-Related Quality of Life of Sarcoma Patients and Survivors In
    Cancers 2020, 12 S1 of S7 Supplementary Materials The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of A Nationwide Observational Study (PROSa) Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I. Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler and the PROSa study group Includes Entities We included sarcomas according to the following WHO classification. - Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 p. (World Health Organization classification of tumours). - Kurman RJ, International Agency for Research on Cancer, World Health Organization, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 p. (World Health Organization classification of tumours). - Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19. - World Health Organization, Swerdlow SH, International Agency for Research on Cancer, editors. WHO classification of tumours of haematopoietic and lymphoid tissues: [... reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 27, 2007]. 4. ed.
    [Show full text]
  • Uterine Adenocarcinoma with Prominent Desmoplasia in a Geriatric Miniature Pig
    NOTE Pathology Uterine Adenocarcinoma with Prominent Desmoplasia in a Geriatric Miniature Pig Hossain Md. GOLBAR1), Takeshi IZAWA1), Mitsuru KUWAMURA1), Shu ITO2) and Jyoji YAMATE1)* 1)Laboratory of Veterinary Pathology, Life and Environmental Sciences, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano, Osaka 598–8531 and 2)Adventure World AWS Co., Ltd., Shirahama, Nishimuro-Gun, Wakayama 649–2201, Japan (Received 25 August 2009/Accepted 18 October 2009/Published online in J-STAGE 27 November 2009) ABSTRACT. A 10-year-old miniature sow was died, showing inappetence and weight loss. Grossly, neoplastic enlargement of the uterus was found. Histopathologically, the lesions consisted of acinar, ductular and cystic proliferations of mono- and multilayered epithelial cells; these cells reacted immunohistochemically strongly with three different cytokeratin antibodies, and occasionally to vimentin. Myo- fibroblastic desmoplastic cells, positive to -smooth muscle actin, were present among neoplastic cells. Metastatic lesions were seen in the lungs and liver. Based on these findings, a diagnosis of uterine adenocarcinoma with marked desmoplasia was made. This case is the second report of uterine adenocarcinoma in the miniature pig. KEY WORDS: desmoplasia, miniature pig, uterine adenocarcinoma. J. Vet. Med. Sci. 72(2): 253–256, 2010 Uterine adenocarcinomas are uncommon neoplasms in Carpinteria, CA, U.S.A.), anti-CK19 (1:100; Novocastra most animals with the exception in rabbits and cattle [6, 13]. Laboratories Ltd., Newcastle, U.K.), anti-AE1/AE3 (predi- Woman cases are the most common invasive cancers of the lution; Dako), anti-vimentin (1: 400; Dako) and anti-- genital tract [3]. To our knowledge, there are two cases of smooth muscle actin (-SMA) (1:100; Dako).
    [Show full text]
  • Soft Tissue Sarcoma Classifications
    Soft Tissue Sarcoma Classifications Contents: 1. Introduction 2. Summary of SSCRG’s decisions 3. Issue by issue summary of discussions A: List of codes to be included as Soft Tissue Sarcomas B: Full list of codes discussed with decisions C: Sarcomas of neither bone nor soft tissue D: Classifications by other organisations 1. Introduction We live in an age when it is increasingly important to have ‘key facts’ and ‘headline messages’. The national registry for bone and soft tissue sarcoma want to be able to produce high level factsheets for the general public with statements such as ‘There are 2000 soft tissue sarcomas annually in England’ or ‘Survival for soft tissue sarcomas is (eg) 75%’ It is not possible to write factsheets and data briefings like this, without a shared understanding from the SSCRG about which sarcomas we wish to include in our headline statistics. The registry accepts that soft tissue sarcomas are a very complex and heterogeneous group of cancers which do not easily reduce to headline figures. We will still strive to collect all data from cancer registries about anything that is ‘like a sarcoma’. We will also produce focussed data briefings on sites such as dermatofibrosarcomas and Kaposi’s sarcomas – the aim is not to forget any sites we exclude! The majority of soft tissue sarcomas have proved fairly uncontroversial in discussions with individual members of the SSCRG, but there were 7 particular issues it was necessary to make a group decision on. This paper records the decisions made and the rationale behind these decisions. 2. Summary of SSCRG’s decisions: Include all tumours with morphology codes as listed in Appendix A for any cancer site except C40 and C41 (bone).
    [Show full text]
  • Transcriptional Regulation of IGF-I Receptor Gene Expression by Novel Isoforms of the EWS-WT1 Fusion Protein
    Oncogene (2002) 21, 1890 ± 1898 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein Ina Finkeltov1, Scott Kuhn3,4, Tova Glaser1, Gila Idelman1, John J Wright2, Charles T Roberts Jr3 and Haim Werner*,1 1Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, 69978 Israel; 2Medicine Branch, Division of Clinical Science, National Cancer Institute, NIH, Bethesda, Maryland MD 20889, USA; 3Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon OR 97201, USA The EWS family of genes is involved in numerous Werner et al., 1994a). In addition to its central role in chromosomal translocations that are characteristic of a normal growth processes, the IGF-I-R plays a pivotal variety of sarcomas. A recently described member of this role in malignant transformation (Baserga et al., 1994; group is desmoplastic small round cell tumor (DSRCT), Grimberg and Cohen, 2000; Werner and LeRoith, which is characterized by a recurrent t(11;22)(p13;q12) 1996). The IGF-I-R is highly expressed in most tumors translocation that fuses the 5' exons of the EWS gene to and cancer cell lines, where it functions as a potent the 3' exons of the WT1 gene. The originally described antiapoptotic agent, conferring enhanced survival to chimera comprises exons 1 ± 7 of EWS and exons 8 ± 10 malignant cells (Resnico et al., 1995; Werner and of WT1. We have previously reported that the WT1 LeRoith, 1997). Transcription of the IGF-I-R gene is protein represses the expression of the IGF-I receptor negatively regulated by a number of tumor suppres- gene, whereas the EWS(1 ± 7)-WT1(8 ± 10) fusion protein sors, including p53, BRCA1 and WT1 (Maor et al., activates IGF-I receptor gene expression.
    [Show full text]
  • The Dynamic Interaction Between Extracellular Matrix Remodeling and Breast Tumor Progression
    cells Review The Dynamic Interaction between Extracellular Matrix Remodeling and Breast Tumor Progression Jorge Martinez 1,* and Patricio C. Smith 2,* 1 Cell Biology Laboratory, INTA, University of Chile, Santiago 7810000, Chile 2 School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile * Correspondence: [email protected] (J.M.); [email protected] (P.C.S.); Tel.: + 56-2-2987-1419 (J.M.); +56-2-2354-8400 (P.C.S.) Abstract: Desmoplastic tumors correspond to a unique tissue structure characterized by the abnormal deposition of extracellular matrix. Breast tumors are a typical example of this type of lesion, a property that allows its palpation and early detection. Fibrillar type I collagen is a major component of tumor desmoplasia and its accumulation is causally linked to tumor cell survival and metastasis. For many years, the desmoplastic phenomenon was considered to be a reaction and response of the host tissue against tumor cells and, accordingly, designated as “desmoplastic reaction”. This notion has been challenged in the last decades when desmoplastic tissue was detected in breast tissue in the absence of tumor. This finding suggests that desmoplasia is a preexisting condition that stimulates the development of a malignant phenotype. With this perspective, in the present review, we analyze the role of extracellular matrix remodeling in the development of the desmoplastic response. Importantly, during the discussion, we also analyze the impact of obesity and cell metabolism as critical drivers of tissue remodeling during the development of desmoplasia. New knowledge derived from the dynamic remodeling of the extracellular matrix may lead to novel targets of interest for early diagnosis or therapy in the context of breast tumors.
    [Show full text]
  • About Soft Tissue Sarcoma Overview and Types
    cancer.org | 1.800.227.2345 About Soft Tissue Sarcoma Overview and Types If you've been diagnosed with soft tissue sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Soft Tissue Sarcoma? Research and Statistics See the latest estimates for new cases of soft tissue sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Soft Tissue Sarcomas ● What's New in Soft Tissue Sarcoma Research? What Is a Soft Tissue Sarcoma? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 There are many types of soft tissue tumors, and not all of them are cancerous. Many benign tumors are found in soft tissues. The word benign means they're not cancer. These tumors can't spread to other parts of the body. Some soft tissue tumors behave 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 in ways between a cancer and a non-cancer. These are called intermediate soft tissue tumors. When the word sarcoma is part of the name of a disease, it means the tumor is malignant (cancer).A sarcoma is a type of cancer that starts in tissues like bone or muscle. Bone and soft tissue sarcomas are the main types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • Stage I Clear Cell Sarcoma of the Kidney: Is It the Time for a Less Intensive Adjuvant Treatment?
    Editorial Stage I clear cell sarcoma of the kidney: is it the time for a less intensive adjuvant treatment? Filippo Spreafico1, Lorenza Gandola2, Fraia Melchionda3 1Pediatric Oncology Unit, Hematology and Pediatric Onco-Hematology Department, 2Pediatric Radiotherapy Unit, Department of Radiology/ Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 3Pediatric Oncology and Hematology Unit “Lalla Seràgnoli”, Departement of Pediatrics, University of Bologna, Sant’Orsola-Malpighi Hospital, Bologna, Italy Correspondence to: Filippo Spreafico, MD. Fondazione IRCCS Istituto Naizonale dei Tumori, Milano, Italy. Email: [email protected]. Abstract: Clear cell sarcoma of the kidney (CCSK) is a rare type of renal tumor, comprising 2% to 5% of all primary renal tumors in children. Despite the label of “unfavorable” tumor, with recent multimodality treatment schedules, including radiotherapy and multi-agent chemotherapy, disease free survival rates approaching 80% can be achieved. Younger age at tumor diagnosis and advanced-stage disease represent adverse prognostic factors. Of note, as a consequence of oncologic therapies a number of surviving patients have suffered from late sequelae on the musculoskeletal, gastrointestinal, hepatic, endocrine and cardiovascular function, or developed second tumors. Improved survival rates and a deeper knowledge of iatrogenic complications have promoted the awareness of a sequential reduction of treatment intensity, at least for low-stage CCSK, above all focusing on the abolition of flank radiation therapy (RT). It is fundamental to recognize that the rarity of this tumor calls for international cooperation trough controlled clinical trials, and without forgetting the key importance of a correct histological diagnosis and adequate surgical staging. The recent recognition of CCSK specific chromosomal translocation might help to guide targeted therapies complementary to conventional chemotherapy and radiotherapy.
    [Show full text]
  • Histopathology of Barrett's Esophagus and Early-Stage
    Review Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review Feng Yin, David Hernandez Gonzalo, Jinping Lai and Xiuli Liu * Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA; fengyin@ufl.edu (F.Y.); hernand3@ufl.edu (D.H.G.); jinpinglai@ufl.edu (J.L.) * Correspondence: xiuliliu@ufl.edu; Tel.: +1-352-627-9257; Fax: +1-352-627-9142 Received: 24 October 2018; Accepted: 22 November 2018; Published: 27 November 2018 Abstract: Esophageal adenocarcinoma carries a very poor prognosis. For this reason, it is critical to have cost-effective surveillance and prevention strategies and early and accurate diagnosis, as well as evidence-based treatment guidelines. Barrett’s esophagus is the most important precursor lesion for esophageal adenocarcinoma, which follows a defined metaplasia–dysplasia–carcinoma sequence. Accurate recognition of dysplasia in Barrett’s esophagus is crucial due to its pivotal prognostic value. For early-stage esophageal adenocarcinoma, depth of submucosal invasion is a key prognostic factor. Our systematic review of all published data demonstrates a “rule of doubling” for the frequency of lymph node metastases: tumor invasion into each progressively deeper third of submucosal layer corresponds with a twofold increase in the risk of nodal metastases (9.9% in the superficial third of submucosa (sm1) group, 22.0% in the middle third of submucosa (sm2) group, and 40.7% in deep third of submucosa (sm3) group). Other important risk factors include lymphovascular invasion, tumor differentiation, and the recently reported tumor budding. In this review, we provide a concise update on the histopathological features, ancillary studies, molecular signatures, and surveillance/management guidelines along the natural history from Barrett’s esophagus to early stage invasive adenocarcinoma for practicing pathologists.
    [Show full text]
  • The Role of Tumor Desmoplasia in Nanoparticle Delivery of Drugs and Genes
    THE ROLE OF TUMOR DESMOPLASIA IN NANOPARTICLE DELIVERY OF DRUGS AND GENES Lei Miao A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Division of Molecular Pharmaceutics in the Eshelman School of Pharmacy Chapel Hill 2016 Approved by: Leaf Huang Philip C. Smith Elena V. Batrakova Xiao Xiao William Y. Kim © 2016 Lei Miao ALL RIGHTS RESERVED ii ABSTRACT Lei Miao: The Role of Tumor Desmoplasia in Nanoparticle Delivery of Drugs and Genes (Under the direction of Leaf Huang) In desmoplastic tumors, stroma cells capture nanoparticles (NPs), preventing them from reaching tumor cells, resulting in compromised anti-tumor efficacy. This dissertation focuses on understanding the basis role of tumor associated fibroblasts (TAFs), one of the major stroma cells constituting desmoplasia, in NP delivery and tumor resistance, as well as proposing strategies to overcome the TAF-elicited barriers and improve efficacy. While the capture of therapeutic NPs in TAFs interferes tumor-stroma crosstalk and inhibits tumor progression, we found that the chronic exposure of NPs paradoxically induced the secretion of survival factors (e.g., Wnt16) from the damaged TAFs, facilitating tumor proliferation and metastasis. Therefore, we proposed the delivery of siRNA against Wnt16 to TAFs via the off-target capture, to downregulate this survival factor. The priming of damaged fibroblasts could synergize with a nanoformulation of cisplatin, and benefit the treatment of a desmoplastic bladder cancer xenograft (UMUC3/3T3). Since the off-target delivery of NPs have been verified, we further utilized the same rationale to generate a group of tumor-suppressive TAFs through transfecting TAFs with a plasmid encoding highly secretable TNF-related apoptosis-inducing ligand (sTRAIL).
    [Show full text]
  • Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Clear Cell Sarcoma Models
    1751 Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Shuzhen Liu, Hongwei Cheng, Wanda Kwan, inhibitors increased expression of SOX9, MYOD1, and Joanna M. Lubieniecka, and Torsten O. Nielsen PPARG and decreased EWS-ATF1 expression in clear cell sarcoma cells. Histone deacetylase inhibitors show prom- Genetic Pathology Evaluation Centre, University of British ising preclinical activity in multiple clear cell sarcoma Columbia, Vancouver, British Columbia, Canada models. [Mol Cancer Ther 2008;7(6):1751–61] Abstract Introduction Clear cell sarcoma is an aggressive malignancy occurring Clear cell sarcoma typically presents in the distal extrem- most commonly in the distal extremities of young adults, ities of young adult patients and is characterized by characterized by t(12;22)(q13;q12) creating the chimeric t(12;22)(q13;q12) (ref. 1). This translocation fuses the 5¶ fusion oncoprotein EWS-ATF1. We assessed growth portion of the Ewing sarcoma (EWSR1) oncogene on inhibition and differentiation effects of histone deacety- chromosome 22q with the 3¶ portion of the activating lase inhibitors MS-275 and romidepsin (depsipeptide, transcription factor 1 (ATF1) oncogene on chromosome FK228) on clear cell sarcoma cells and evaluated drug 12q, resulting in the EWS-ATF1 chimeric fusion oncopro- sensitivity among related translocation-associated sarco- tein. Treatment for clear cell sarcoma is wide excision of mas and other cell models. Three clear cell sarcoma cell the tumor as soon as the diagnosis is established, with lines, seven other sarcomas, six nonsarcoma malignant neoadjuvant or adjuvant radiation therapy to improve the cell lines, and two nonneoplastic mesenchymal cell rate of local control.
    [Show full text]
  • CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction In
    Published OnlineFirst June 30, 2020; DOI: 10.1158/0008-5472.CAN-19-2745 CANCER RESEARCH | GENOME AND EPIGENOME CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma Toshihiro Morita1, Yuzo Kodama1,2, Masahiro Shiokawa1, Katsutoshi Kuriyama1, Saiko Marui1, Takeshi Kuwada1, Yuko Sogabe1, Tomoaki Matsumori1, Nobuyuki Kakiuchi1, Teruko Tomono1, Atsushi Mima1, Tatsuki Ueda1, Motoyuki Tsuda1, Yuki Yamauchi1, Yoshihiro Nishikawa1, Yojiro Sakuma1, Yuji Ota1, Takahisa Maruno1, Norimitsu Uza1, Takashi Nagasawa3, Tsutomu Chiba1,4, and Hiroshi Seno1 ABSTRACT ◥ Pancreatic ductal adenocarcinoma (PDAC) features abundant fibroblasts, and markedly less deposition of ECM. In vitro, KPC- stromal cells with an excessive extracellular matrix (ECM), termed Cxcr4-KO tumor cells exhibited higher proliferative and migratory the desmoplastic reaction. CXCR4 is a cytokine receptor for stromal activity than KPC-Cxcr4-WT tumor cells. Myofibroblasts induced cell-derived factor-1 (CXCL12) expressed in PDAC, but its invasion activity in KPC-Cxcr4-WT tumor cells, showing an epi- roles in PDAC and the characteristic desmoplastic reaction remain thelial–mesenchymal interaction, whereas KPC-Cxcr4-KO tumor unclear. Here, we generated a mouse model of PDAC with condi- cells were unaffected by myofibroblasts, suggesting their unique tional knockout of Cxcr4 (KPC-Cxcr4-KO) by crossing Cxcr4 nature. In human pancreatic cancer, undifferentiated carcinoma did flox mice with Pdx1-Cre;KrasLSL-G12D/þ;Trp53LSL-R172H/þ not express CXCR4 and
    [Show full text]